(Reuters) -Lykos Therapeutics said on Thursday it would reduce its workforce by 75% and initiate some executive changes, days after the U.S. Food and Drug Administration declined approval for its MDMA-based treatment for post-traumatic stress disorder.

Lykos, formerly known as MAPS Public Benefit Corp, said its founder Rick Doblin was leaving the company's board.

It said it was bringing in David Hough, former vice president for research and development at Johnson & Johnson, to lead and oversee Lykos's clinical development program.